Abstract
Objective: To evaluate Minimal Inhibitory Concentrations of ceftaroline, teicoplanin & daptomycin for treatment of methicillinresistant Staphylococcus aureus in a tertiary care setting.Study Design: Experimental study.Place and Duration of Study: Department of Pathology, Microbiology Laboratory from Nov 2021 to Oct 2022.Methodology: All the isolated Staph. aureus was processed and identified by colony morphology on blood agar, gram stain,and biochemical tests i.e., catalase, coagulase and DNAase test. Minimal Inhibitory Concentration was evaluated using Estrips for ceftaroline, teicoplanin & daptomycin for all the MRSA strains during the study period.Results: A total of 924 S.aureus strains were processed, and 270 (29.22%) MRSA were recovered during the study period. Thehighest percentage 50 was observed in sputum (n=2), followed by 41.66% in endobronchial washing (n=10), pus 160 (31.25%),tissue 30 (31.25%), pus swab 50 (29.76%), high vaginal swab 2 (25%), and least in blood 16 (14.54%). MICs for all the MRSAisolates to teicoplanin were in susceptible range (≤8µg/ml). MIC of 22 (8.14%) and 14 (5.18%) MRSA isolates for Ceftarolineand daptomycin were in susceptible dose-dependent (SDD=2-4µg/ml) range.Conclusion: The diagnostic modality, antimicrobial susceptibility testing, and MIC determination were found to be the bestapproach for adequate management of MRSA.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
